Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1697 Phase 1 Study in Advanced Solid Tumors
NCT03515824Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Biologic
- Countries
- 2
01
Overview
Phase 1, open-label trial of MK-1697 in solid tumor (advanced stage), colorectal cancer (CRC) and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1, Number of Participants Who Experienced At Least One Adverse Event (AE) up to 9 months and 1 more. Started Aug 2018; status: terminated.
02
Drugs
MK-1697
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03515824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515824.